Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial

Abstract

Objectives To determine the efficacy of intraoperative treatment with low dose tranexamic acid in reducing the rate of perioperative transfusions in patients undergoing radical retropubic prostatectomy.Design Double blind, parallel group, randomised, placebo controlled trial.Setting One university hospital in Milan, Italy.Participants 200 patients older than 18 years and undergoing radical retropubic prostatectomy agreed to participate in the trial. Exclusion criteria were atrial fibrillation, coronary artery disease treated with drug eluting stent, severe chronic renal failure, congenital or acquired thrombophilia, and known or suspected allergy to tranexamic acid.Interventions Intravenous infusion of tranexamic acid or equivalent volume of placebo (saline) according to the following protocol: loading dose of 500 mg tranexamic acid 20 minutes before surgery followed by continuous infusion of tranexamic acid at 250 mg/h during surgery.Main outcome measures Primary outcome: number of patients receiving blood transfusions perioperatively. Secondary outcome: intraoperative blood loss. Six month follow-up to assess long term safety in terms of mortality and thromboembolic events.Results All patients completed treatment and none was lost to follow-up. Patients transfused were 34 (34%) in the tranexamic acid group and 55 (55%) in the control group (absolute reduction in transfusion rate 21% (95% CI 7% to 34%); relative risk of receiving transfusions for patients treated with tranexamic acid 0.62 (0.45 to 0.85); number needed to treat 5 (3 to 14); P=0.004). At follow-up, no patients died and the occurrence of thromboembolic events did not differ between the two groups.Conclusions Intraoperative treatment with low dose tranexamic acid is safe and effective in reducing the rate of perioperative blood transfusions in patients undergoing radical retropubic prostatectomy.Trial registration ClinicalTrials.gov identifier NCT00670345.

Perioperative Blood Transfusion and Radical Cystectomy: Does Timing of Transfusion Affect Bladder Cancer Mortality?

“…Recent trials using tranexamic acid in ovarian cancer and prostate cancer surgery demonstrated decreased intraoperative blood loss and reduced transfusion rate [27,28]. This strategy is now being tested in RC patients in the Canadian multicenter Trial to Assess Chelation Therapy (TACT) [29].…”

Efficacy of Tranexamic acid in Reducing Blood Loss During Maxillofacial Trauma Surgery–A Pilot Study

“…Thaller and Beal also present detailed reports of six patients who have succumbed to haemorrhagic complications or had life-threatening exsanguinations secondary to isolated facial trauma [5]. TXA has also been reported to be successful in reducing haemorrhage in several surgical procedures including craniofacial surgery [6], knee surgery [7], spine surgery [8], prostrate surgeries [9] and the like besides trauma management. TXA oral rinse has been used for preventing excessive haemorrhage for patients with coagulopathies [10][11][12][13][14][15][16].…”

Role of Tranexamic Acid in Treatment of Patients with Epidural Hematoma

“…These patients are treated with conservative proceedings such as antifibrinolytic agents. TXA, an antifibrinolytic drug, reported to be safe in most prior studies, had no serious side effects in our study [9,10]. The highest effectiveness of TXA is at first four hours after trauma and injection, so in our study, we started TXA administration immediately after diagnosis of EDH in patients [8].…”